Citius Oncology Inc.CTORNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -19.97% | +7.55% | +7.55% | +13.13% | +22.24% |
| Weighted Average Shares Diluted Growth | -19.97% | +7.55% | +7.55% | +13.13% | +22.24% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -714.72% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -714.72% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +169.53% | +57.42% |
| Asset Growth | +89.55% | +86.97% | +83.39% | +19.64% | +21.54% |
| Book Value per Share Growth | +127.04% | +66.99% | +76.88% | -14.04% | +15.74% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +10.10% | +132.73% | -17.07% | -16.97% | -19.47% |
| SG&A Expenses Growth | +49.36% | +29.60% | +14.56% | -32.34% | +32.84% |